Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $39.8K in total
- 8
- 13F holdersQ2 2026, +2 vs. previous quarter
- 46
- 13F valueReported value at the end of Q2 2026
- $38.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ACRV, Q2 2026
No superinvestor reported holding ACRV at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Acrivon Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 (view filing)4:14 PM ET | Aug 25 | 2 days | Blume-Jensen Peter and 1 otherPresident and CEO | SSale | −14.0K | $2.21 | −$31.0K | −0.6%2.23M after | |
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Peterson KatharineChief Accounting Officer | SSale | −101 | $2.01 | −$203.01 | −0.6%18.0K after | |
| Aug 20, 2026 (view filing)4:09 PM ET | Aug 18 | 2 days | Miller MaryChief Legal Officer | SSale | −185 | $2.01 | −$371.85 | −0.2%82.0K after | |
| Aug 20, 2026 (view filing)4:08 PM ET | Aug 18 | 2 days | Gamelin ErickChief Development Officer | SSale | −400 | $2.01 | −$804 | −0.8%52.6K after | |
| Aug 20, 2026 (view filing)4:07 PM ET | Aug 18 | 2 days | Devroe EricChief Operating Officer | SSale | −604 | $2.01 | −$1.21K | −0.4%146.3K after | |
| Aug 20, 2026 (view filing)4:07 PM ET | Aug 18 | 2 days | Blume-Jensen Peter and 1 otherPresident and CEO | SSale | −1.23K | $2.01 | −$2.47K | −0.1%2.24M after | |
| Aug 20, 2026 (view filing)4:07 PM ET | Aug 18 | 2 days | Blume-Jensen Peter and 1 otherPresident and CEO | SSale | −484 | $2.01 | −$972.84 | −0.1%385.9K after | |
| Aug 6, 2026 (view filing)4:34 PM ET | Aug 4 | 2 days | Levy Adam D.Chief Financial Officer | SSale | −1.14K | $1.57 | −$1.79K | −1.7%66.0K after | |
| Jul 23, 2026 (view filing)4:28 PM ET | Jul 21 | 2 days | Miller MaryChief Legal Officer | SSale | −573 | $1.76 | −$1.01K | −0.7%82.2K after | |
| Jan 16, 2026 (view filing)4:02 PM ET | Jan 14 | 2 days | Blume-Jensen Peter and 1 otherPresident and CEO | PPurchase | +49.0K | $1.68 | +$82.1K | +2.4%2.10M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Acrivon Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,229,396 | $21.8M | 0.19% | +3,888,888+46.6% | Added |
| Sands Capital Ventures, LLC | 2,289,271 | $4.07M | 0.66% | +166,666+7.9% | Added |
| Acadian Asset Management LLC | 1,165,119 | $2.07M | 0.00% | +319,146+37.7% | Added |
| Vanguard Capital Management LLC | 952,008 | $1.69M | 0.00% | +229,973+31.9% | Added |
| Wellington Management Group LLP | 888,130 | $1.58M | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 758,863 | $1.35M | 0.00% | +423+0.1% | Added |
| Two Sigma Investments, LP | 641,498 | $1.14M | 0.00% | +252,103+64.7% | Added |
| Marshall Wace, LLP | 531,856 | $946.7K | 0.00% | −28,580−5.1% | Reduced |
| Bridgeway Capital Management, LLC | 378,900 | $674.4K | 0.01% | +220,000+138.5% | Added |
| Geode Capital Management, LLC | 265,241 | $472.3K | 0.00% | +28,850+12.2% | Added |